Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 93-98

  Henrich, Timothy J ^a,b   Ribaudo, Heather J ^c   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INHIBITORY QUOTIENT; INSTANTANEOUS INHIBITORY POTENTIAL; INTERMETHOD COMPARISON; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LINEAR MODELS; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD;

EID: 77953792513     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653430     Document Type: Article

References (29)

1. Hoefhagel JG, Koopmans PP, Burger DM, Schuurman R, Galama JM. Role of the inhibitory quotient, in HIV therapy. Antiv Ther 2005; 10: 879-892 (Pubitemid 43076339)
2. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis 2006; 6: 215-225
3. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14: 762-766 (Pubitemid 351951518)
4. Hill AV. The possible effects of the aggregation of the molecules of hemoglobin on its dissociation curves. Proc Physiol Soc 1910; 4-7.
5. Chou TC. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253-276
6. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
7. McMahon MA, Shen L, Siliciano RF. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis 2009; 22: 574-582
8. Shen L, Rabi SA, Siliciano RE A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 2009; 30: 610-616
9. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201. (Pubitemid 38917996)
11. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-1861
12. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-1019
13. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of firstline antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263 (Pubitemid 38496486)
14. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873
15. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106 (Pubitemid 351679596)
16. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35: 22-32. (Pubitemid 38044778)
17. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368: 476-482 (Pubitemid 44160731)
18. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397
19. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that, of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58. (Pubitemid 47023100)
20. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046 (Pubitemid 34680595)
21. Molina JM., Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1 -infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655
22. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50: 367-374
23. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCminl Trial. J Infect Dis 2003; 188: 635-642 (Pubitemid 37115175)
24. Youle M, Gerstoft J, Fox Z, et al. The final week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/10) [abstract LB23]. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris). 2003.
25. Dragsted UB, Gerstoft. J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1 -infected patients: the MaxCmin2 trial. Antivir Ther 2005; 10: 735-813 (Pubitemid 41376853)
26. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
27. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [abstract 176]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). 2003.
28. Uitenbroek DG. SISA: Simple Interactive Statistical Analysis. Hilversum, The Netherlands. http://www.quantitativeskills.com/sisa/.
29. Hughes MD, DeGruttola V, Welles SL. Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10(Suppl 2):S1-8.